Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$40.39 +1.9%	$32.24	$16.50 ▼ $43.58	$3.45B	N/A	11,795 shs	7,108 shs
MRUS Merus	$63.26 +3.0%	$52.47	$33.19 ▼ $63.51	$4.25B	1	733,104 shs	1.06 million shs
RARE Ultragenyx Pharmaceutical	$26.31 -4.0%	$35.65	$26.01 ▼ $60.37	$2.59B	0.26	976,201 shs	3.90 million shs
SYRE Spyre Therapeutics	$16.29 -3.6%	$15.77	$10.91 ▼ $40.26	$1.02B	2.68	576,212 shs	333,165 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+2.59%	-2.75%	+25.22%	+111.65%	+3,961,999,900.00%
MRUS Merus	+8.72%	+11.49%	+15.75%	+42.68%	+8.65%
RARE Ultragenyx Pharmaceutical	+0.37%	-11.67%	-25.23%	-23.20%	-37.55%
SYRE Spyre Therapeutics	+4.26%	+5.83%	+11.26%	+33.31%	-46.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRUS Merus	1.9476 of 5 stars	3.6	1.0	0.0	0.0	2.1	2.5	0.0
RARE Ultragenyx Pharmaceutical	4.3899 of 5 stars	4.5	1.0	0.0	3.8	2.2	2.5	0.6
SYRE Spyre Therapeutics	1.9128 of 5 stars	3.6	0.0	0.0	0.0	1.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
MRUS Merus	3.14	Buy	$84.64	33.79% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$83.64	217.91% Upside
SYRE Spyre Therapeutics	3.29	Buy	$53.40	227.81% Upside

Current Analyst Ratings Breakdown

Latest SYRE, RARE, AAPG, and MRUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$35.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
7/10/2025	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$88.00 ➝ $65.00
6/20/2025	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/9/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$64.00 ➝ $65.00
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
5/5/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
4/28/2025	MRUS Merus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	26.19	N/A	N/A	$0.48 per share	84.15
MRUS Merus	$36.13M	121.18	N/A	N/A	$9.46 per share	6.69
RARE Ultragenyx Pharmaceutical	$560.23M	4.44	N/A	N/A	$2.76 per share	9.53
SYRE Spyre Therapeutics	$890K	1,103.33	N/A	N/A	$7.04 per share	2.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MRUS Merus	-$215.33M	-$4.08	0.00	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)
SYRE Spyre Therapeutics	-$208.02M	-$3.77	N/A	N/A	N/A	N/A	-77.46%	-41.06%	8/6/2025 (Estimated)

Latest SYRE, RARE, AAPG, and MRUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q1 2025	MRUS Merus	-$1.17	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	RARE Ultragenyx Pharmaceutical	-$1.27	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	SYRE Spyre Therapeutics	-$0.68	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/8/2025	Q1 2025	SYRE Spyre Therapeutics	-$0.76	-$0.74	+$0.02	-$0.74	N/A	N/A
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
MRUS Merus	N/A	5.86	5.86
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24
SYRE Spyre Therapeutics	N/A	8.06	8.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
MRUS Merus	96.14%
RARE Ultragenyx Pharmaceutical	97.67%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
MRUS Merus	4.57%
RARE Ultragenyx Pharmaceutical	5.50%
SYRE Spyre Therapeutics	15.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.12 million	N/A	N/A
MRUS Merus	37	69.21 million	66.05 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	94.54 million	89.34 million	Optionable
SYRE Spyre Therapeutics	73	60.28 million	50.98 million	Optionable

SYRE, RARE, AAPG, and MRUS Headlines

Recent News About These Companies

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by Analysts

July 17 at 4:09 AM | marketbeat.com

Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation

July 16 at 6:35 AM | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Shares Down 7.8% - Time to Sell?

July 15 at 5:49 PM | marketbeat.com

SYRE - Spyre Therapeutics Inc Trailing Returns - Morningstar

July 4, 2025 | morningstar.comM

Spyre Therapeutics Announces Grants of Inducement Awards

July 3, 2025 | globenewswire.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from Analysts

June 22, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)

June 20, 2025 | theglobeandmail.com

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

June 18, 2025 | seekingalpha.com

Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...

June 17, 2025 | finanznachrichten.de

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

June 17, 2025 | prnewswire.com

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

June 16, 2025 | prnewswire.com

Spyre Therapeutics Announces Grants of Inducement Awards

June 6, 2025 | prnewswire.com

Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know

May 30, 2025 | zacks.com

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 28, 2025 | prnewswire.com

How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%

May 13, 2025 | zacks.com

Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)

May 10, 2025 | theglobeandmail.com

Spyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025 | finanznachrichten.de

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025 | prnewswire.com

Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Down 5.11%

May 7, 2025 | aaii.comA

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

May 5, 2025 | prnewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO), Spyre Therapeutics (SYRE) and Herbalife (HLF)

May 3, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
By Sam Quirke | June 30, 2025
View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
Why Qualcomm’s Latest Price Target Can't Be Ignored
By Sam Quirke | June 24, 2025
View Why Qualcomm’s Latest Price Target Can't Be Ignored
MP Materials Stock Booms on New Government Positioning
By Gabriel Osorio-Mazilli | July 14, 2025
View MP Materials Stock Booms on New Government Positioning
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
By Ryan Hasson | July 7, 2025
View Top 5 Undervalued Dividend Stocks With Strong Payout Potential

SYRE, RARE, AAPG, and MRUS Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$40.39 +0.77 (+1.94%)

As of 04:00 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Merus NASDAQ:MRUS

$63.26 +1.82 (+2.96%)

Closing price 04:00 PM Eastern

Extended Trading

$63.24 -0.02 (-0.04%)

As of 07:59 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Ultragenyx Pharmaceutical NASDAQ:RARE

$26.31 -1.10 (-4.01%)

Closing price 04:00 PM Eastern

Extended Trading

$26.20 -0.11 (-0.42%)

As of 07:56 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Spyre Therapeutics NASDAQ:SYRE

$16.29 -0.60 (-3.55%)

Closing price 04:00 PM Eastern

Extended Trading

$17.07 +0.78 (+4.76%)

As of 05:22 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time